GLP-1 drugs like semaglutide and tirzepatide may lower dementia risk for people with obesity or type 2 diabetes, but phase 3 trials show they do not slow early Alzheimer’s progression.
What did the review find?
Researchers analyzed preclinical data, observational cohorts, and clinical trials. They found consistent associations between GLP-1 use and reduced cognitive impairment risk. However, the review, published November 5, could not determine whether the drugs act directly on the brain or through improved cardiometabolic health.
Do the drugs reach the brain?
Animal studies show long-acting GLP-1 agonists preferentially reach the hypothalamus, brainstem, and circumventricular organs. The review reported, citing the review, that evidence of drug exposure in memory-associated regions such as the hippocampus and cortex remains inconsistent.
What did the Alzheimer’s trials show?
EVOKE and EVOKE+ phase 3 trials enrolled 3,808 participants with biomarker-confirmed mild cognitive impairment or mild Alzheimer’s dementia. Over 104 weeks, oral semaglutide did not slow clinical decline or deterioration in daily function.

How do experts interpret the findings?
“While research suggests GLP-1s could reduce brain inflammation, improve blood vessel health, and even protect neurons, much broader, randomized clinical trials on GLP-1s and brain health, including in people with Alzheimer’s disease and other dementias, are needed,” said Sheena Aurora, MD, vice president of Medical Affairs at the Alzheimer’s Association, Healthline reported.
“These findings are interesting, but like many of the other benefits associated with GLP-1 medications, a direct causal relationship has not yet been proven. Rather, the benefits appear to be more closely tied to the reduction in obesity and better control of diabetes.”
Review authors and their industry ties
The review was written by Stina Börchers, Giulia Mazzini, Henrik Zetterberg, and Christoffer Clemmensen, according to the paper published in Science. Their affiliations include the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen and the Sahlgrenska Academy at the University of Gothenburg.
Zetterberg also reported commercial relationships with pharmaceutical companies, including Novo Nordisk, the disclosure notes.
How the review weighed the clinical evidence
They emphasized that the choice of comparison groups mattered because people taking different diabetes drugs can differ in illness severity and other health factors.
What is being tested next?
The Alzheimer’s Association is funding the global phase 3 PROTECT-Cog trial. It will assess whether pairing a multidomain lifestyle intervention with a metabolism-targeting drug such as a GLP-1 can further lower the risk of cognitive decline, mild cognitive impairment, and dementia in at-risk older adults, Healthline reported.
“I often remind my patients that what's good for the heart is generally good for the brain,” Dung Trinh, MD, internist at MemorialCare Medical Group and Chief Medical Officer of Healthy Brain Clinic in Irvine, CA, told Healthline.
The Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen focuses on fundamental research into the biological mechanisms underpinning cardiometabolic diseases such as diabetes, obesity, and cardiovascular disease. As of its April 2023 grant renewal, the Center aims to sort patients into subtypes and identify distinct genetic and molecular markers to advance precision health, moving beyond a “one-size-fits-all” approach, according to Executive Director Professor Juleen R. Zierath.
The Center also works to translate discoveries into transformative treatments, having submitted 10 patents and started five spin-out companies since 2018.
“We're also interested to see whether adding a drug like a GLP-1 to a U.S. POINTER-style lifestyle program improves cognition in at-risk older adults more than the program alone,” Sheena Aurora, MD, vice president of Medical Affairs at the Alzheimer's Association, told Healthline.